New Compound Related to Psychedelic Ibogaine Could Treat Addiction, Depression

Olson Lab

New Compound Related to Psychedelic Ibogaine Could Treat Addiction, Depression

By Andy Fell on December 9, 2020 in Human & Animal Health
 

A non-hallucinogenic version of the psychedelic drug ibogaine has been developed by David Olson and colleagues at the UC Davis Department of Chemistry. The new compound shows potential for treating psychiatric disorders including addiction in animal models and may work by increasing connectivity between nerve cells. Image of nerve cells by Lindsay Cameron, UC Davis.

A non-hallucinogenic version of the psychedelic drug ibogaine, with potential for treating addiction, depression and other psychiatric disorders, has been developed by researchers at the University of California, Davis. A paper describing the work is published Dec. 9 in Nature.

“Psychedelics are some of the most powerful drugs we know of that affect the brain,” said David Olson, assistant professor of chemistry at UC Davis and senior author on the paper. “It’s unbelievable how little we know about them.”

Ibogaine is extracted from the plant Tabernanthe iboga. There are anecdotal reports that it can have powerful anti-addiction effects such as reducing drug cravings and preventing relapse. But there are also serious side-effects, including hallucinations and cardiac toxicity, and the drug is a Schedule 1 controlled substance under U.S. law.

Olson’s laboratory at UC Davis is one of a few in the U.S. licensed to work with Schedule 1 substances. They set out to create a synthetic analog of ibogaine which retained therapeutic properties without the undesired effects of the psychedelic compound. Olson’s team worked through a series of similar compounds by swapping out parts of the ibogaine molecule. They engineered a new, synthetic molecule which they named tabernanthalog or TBG.

Models of anxiety, depression and addiction

Unlike ibogaine, the new molecule is water-soluble and can be synthesized in a single step. Experiments with cell cultures and zebrafish show that it is less toxic than ibogaine, which can cause heart attacks and has been responsible for several deaths.

TBG increased formation of new dendrites (branches) in rat nerve cells, and of new spines on those dendrites. That’s similar to the effect of drugs like ketamine, LSD, MDMA and DMT (the active component in the plant extract ayahuasca) on connections between nerve cells. 

TBG molecule

Tabernanthalog (TBG) was made by swapping out parts of the psychedelic drug ibogaine. Credit: Annie Spikes


TBG did not, however, cause a head twitch response in mice, which is known to correlate with hallucinations in humans.

A series of experiments in rodent models of depression and addiction show that the new drug has promising positive effects. These animal models – conducted in accordance with NIH regulations and reviewed and approved by Institutional Animal Care and Use Committees – remain vital to investigating complex psychiatric disorders.  

Mice trained to drink alcohol cut back their consumption after a single dose of TBG. Rats were trained to associate a light and tone with pressing a lever to get a dose of heroin. When the opiate is taken away, the rats develop signs of withdrawal and press the lever again when given the light and sound cues. Treating the rats with TBG had a long-lasting effect on opiate relapse.

Olson thinks that TBG works by changing the structure of neurons in key brain circuits involved in depression, anxiety, post-traumatic stress disorder and addiction.

“We’ve been focused on treating one psychiatric disease at a time, but we know that these illnesses overlap,” Olson said. “It might be possible to treat multiple diseases with the same drug.”

Indeed, psychedelic therapies have been attracting new interest in recent years. But taking patients on individual ‘trips’ is time consuming and costly, requiring hours of close medical supervision apart from the possible negative effects.

“We need a drug that people can keep in their medicine cabinet and this is a significant step in that direction,” Olson said.

Olson has started a company, Delix Therapeutics Inc., which has licensed TBG-related technology from UC Davis for further development.

Additional coauthors on the paper are: at UC Davis, Lindsay Cameron, Robert Tombari, Alexander Pell, Zefan Hurley, Maxemiliano Vargas, Bianca Yaghoobi, Guoliang Zhang, Jayashri Viswanathan, Lee Dunlap, Brandon Brown, Zachary Rabow, Oliver Fiehn, Heike Wulff and Pamela Lein; Ju Lu, Taohui Liu, Michelle Tjia and Yi Zuo, UC Santa Cruz; Yann Ehinger, Matthew McCarroll, Jack Taylor, Douglas Myers-Turnbull, David Kokel and Dorit Ron, UC San Francisco; Lauren Laskowski, Emilie Anderson and John McCorvy, Medical College of Wisconsin, Milwaukee; and Jamie Peters, University of Colorado Denver. The work was supported by grants from the NIH.

 

This article originally appeared in the UC Davis Human & Animal Health